2026 Q2 -tulosraportti
23 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
3,96%Tuotto/v
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·38 min sitten · MuokattuKim at 19 and her friend A10A, aka comical Ali, are right, I operate all profiles here that don't agree with them 😂😂😂 I fortunately have a lot of profiles to choose from 🤣🤣🤣 I also apologize that I am to blame for Novo's downturn, because of my posts here, knowing that all investors in the USA follow along here 🤣🤣🤣
·49 min sittenIt is incredibly sad to witness that the market has completely lost faith and trust in Novo. Regardless of whether Novo will eventually achieve great success with the pill, the company has contributed to destroying its own image. If one looks at the numbers regarding the Wegovy pill, they are growing proportionally less than the competitor, therefore the result will be that they will lose market share in the long term.
·51 min sitten · MuokattuWe ended in +plus. I repeat: We ended in plus due to 2 good news items The victory together with LLY regarding Compounds Okay prescription data Could lift the price +0.08+ That's damn strong performance!
·46 min sitten · MuokattuWell-known information but nevertheless something to take into account! "The common weekly prescription numbers from analytics firms like IQVIA and Symphony Health significantly underreport the real sales of Novo Nordisk's Wegovy pill (oral semaglutide) in the USA. According to Novo Nordisk's CFO, Karsten Munk Knudsen, the external trackers only capture about 60 % of the real market. While IQVIA and Symphony in August 2026 report around 172,000–176,000 weekly prescriptions, Novo's own internal data shows that the real figure is 265,000 weekly prescriptions in the USA. There are three primary reasons why the analytics firms miss such a large part of the pill sales: 1. The massive shift to telehealth The Wegovy pill is largely distributed through specialized online clinics and telehealth platforms. Many of these digital providers use closed pharmacy networks (so-called partner pharmacies or mail-order solutions), which historically do not fully report their sales data to traditional systems like IQVIA and Symphony. 2. "Self-pay" and Cash channels Since weight loss medication in the USA often has fluctuating insurance coverage, an unusually large proportion of patients pay out of pocket (cash pay). When transactions bypass traditional health insurances (PBMs), the analytics firms' algorithms, which largely rely on insurance claims (claims data), lose track of a large part of the volumes. 3. Easier logistics than injections Unlike traditional Wegovy injections, which require an unbroken cold chain during transport, the pill form is much easier to pack and send by regular mail directly to the patient's door. This has created an explosion in direct-to-consumer distribution (DTC), which effectively moves sales out of physical retail pharmacies, where IQVIA and Symphony have their strongest data coverage. That pill sales are actually about 40 % higher than weekly news headlines suggest also explains why Novo Nordisk earlier this year surprised the market with significant upward adjustments driven specifically by the pill launch.”
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q2 -tulosraportti
23 päivää sitten
‧1 t 2 min
3,75 DKK/osake
Viimeisin osinko
3,96%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·38 min sitten · MuokattuKim at 19 and her friend A10A, aka comical Ali, are right, I operate all profiles here that don't agree with them 😂😂😂 I fortunately have a lot of profiles to choose from 🤣🤣🤣 I also apologize that I am to blame for Novo's downturn, because of my posts here, knowing that all investors in the USA follow along here 🤣🤣🤣
- ·49 min sittenIt is incredibly sad to witness that the market has completely lost faith and trust in Novo. Regardless of whether Novo will eventually achieve great success with the pill, the company has contributed to destroying its own image. If one looks at the numbers regarding the Wegovy pill, they are growing proportionally less than the competitor, therefore the result will be that they will lose market share in the long term.
- ·51 min sitten · MuokattuWe ended in +plus. I repeat: We ended in plus due to 2 good news items The victory together with LLY regarding Compounds Okay prescription data Could lift the price +0.08+ That's damn strong performance!
- ·46 min sitten · MuokattuWell-known information but nevertheless something to take into account! "The common weekly prescription numbers from analytics firms like IQVIA and Symphony Health significantly underreport the real sales of Novo Nordisk's Wegovy pill (oral semaglutide) in the USA. According to Novo Nordisk's CFO, Karsten Munk Knudsen, the external trackers only capture about 60 % of the real market. While IQVIA and Symphony in August 2026 report around 172,000–176,000 weekly prescriptions, Novo's own internal data shows that the real figure is 265,000 weekly prescriptions in the USA. There are three primary reasons why the analytics firms miss such a large part of the pill sales: 1. The massive shift to telehealth The Wegovy pill is largely distributed through specialized online clinics and telehealth platforms. Many of these digital providers use closed pharmacy networks (so-called partner pharmacies or mail-order solutions), which historically do not fully report their sales data to traditional systems like IQVIA and Symphony. 2. "Self-pay" and Cash channels Since weight loss medication in the USA often has fluctuating insurance coverage, an unusually large proportion of patients pay out of pocket (cash pay). When transactions bypass traditional health insurances (PBMs), the analytics firms' algorithms, which largely rely on insurance claims (claims data), lose track of a large part of the volumes. 3. Easier logistics than injections Unlike traditional Wegovy injections, which require an unbroken cold chain during transport, the pill form is much easier to pack and send by regular mail directly to the patient's door. This has created an explosion in direct-to-consumer distribution (DTC), which effectively moves sales out of physical retail pharmacies, where IQVIA and Symphony have their strongest data coverage. That pill sales are actually about 40 % higher than weekly news headlines suggest also explains why Novo Nordisk earlier this year surprised the market with significant upward adjustments driven specifically by the pill launch.”
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
2026 Q2 -tulosraportti
23 päivää sitten
‧1 t 2 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 4.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 5.8. | ||
2026 Q1 -tulosraportti 6.5. | ||
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 |
3,75 DKK/osake
Viimeisin osinko
3,96%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·38 min sitten · MuokattuKim at 19 and her friend A10A, aka comical Ali, are right, I operate all profiles here that don't agree with them 😂😂😂 I fortunately have a lot of profiles to choose from 🤣🤣🤣 I also apologize that I am to blame for Novo's downturn, because of my posts here, knowing that all investors in the USA follow along here 🤣🤣🤣
- ·49 min sittenIt is incredibly sad to witness that the market has completely lost faith and trust in Novo. Regardless of whether Novo will eventually achieve great success with the pill, the company has contributed to destroying its own image. If one looks at the numbers regarding the Wegovy pill, they are growing proportionally less than the competitor, therefore the result will be that they will lose market share in the long term.
- ·51 min sitten · MuokattuWe ended in +plus. I repeat: We ended in plus due to 2 good news items The victory together with LLY regarding Compounds Okay prescription data Could lift the price +0.08+ That's damn strong performance!
- ·46 min sitten · MuokattuWell-known information but nevertheless something to take into account! "The common weekly prescription numbers from analytics firms like IQVIA and Symphony Health significantly underreport the real sales of Novo Nordisk's Wegovy pill (oral semaglutide) in the USA. According to Novo Nordisk's CFO, Karsten Munk Knudsen, the external trackers only capture about 60 % of the real market. While IQVIA and Symphony in August 2026 report around 172,000–176,000 weekly prescriptions, Novo's own internal data shows that the real figure is 265,000 weekly prescriptions in the USA. There are three primary reasons why the analytics firms miss such a large part of the pill sales: 1. The massive shift to telehealth The Wegovy pill is largely distributed through specialized online clinics and telehealth platforms. Many of these digital providers use closed pharmacy networks (so-called partner pharmacies or mail-order solutions), which historically do not fully report their sales data to traditional systems like IQVIA and Symphony. 2. "Self-pay" and Cash channels Since weight loss medication in the USA often has fluctuating insurance coverage, an unusually large proportion of patients pay out of pocket (cash pay). When transactions bypass traditional health insurances (PBMs), the analytics firms' algorithms, which largely rely on insurance claims (claims data), lose track of a large part of the volumes. 3. Easier logistics than injections Unlike traditional Wegovy injections, which require an unbroken cold chain during transport, the pill form is much easier to pack and send by regular mail directly to the patient's door. This has created an explosion in direct-to-consumer distribution (DTC), which effectively moves sales out of physical retail pharmacies, where IQVIA and Symphony have their strongest data coverage. That pill sales are actually about 40 % higher than weekly news headlines suggest also explains why Novo Nordisk earlier this year surprised the market with significant upward adjustments driven specifically by the pill launch.”
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt